Literature DB >> 33642429

Persistence of Anti-Rubella Immunoglobulin G Antibody Titers in Young Adults Involved in a Short-Term Periodic Immunization in Japan.

Hiraku Sasaki1, Tomoko Fukunaga2, Ai Asano2, Mayu Tsumita1, Yoshio Suzuki3, Nobuto Shibata4.   

Abstract

In Japan, several rubella outbreaks in adults have erupted due to insufficient immunity against rubella virus (RUBV). Although selective immunization is being promoted along with routine rubella vaccination as its eradication strategy, serosurveillance against RUBV needs to be implemented in the generations corresponding to the vaccination transition period. In this study, a survey of anti-rubella immunoglobulin G (IgG) antibody titers was conducted among young adults involved in the transitional periods of the routine rubella vaccination program. Specifically, serosurveillance was performed in 370 healthy young adults aged 18-20 years, wherein their serum samples were analyzed using an enzyme immunoassay to determine rubella-specific IgG antibody titers. Although multiple regression analysis revealed significant differences only in medical history, more than 90% of participants exhibited seropositivity, excluding those who received a single-dose vaccine alone. Based on elapsed periods after the last vaccination, rubella-specific IgG antibody titers in less than a 6-year period were higher than those in more than a 10-year period. Although almost all study participants in the transitional period had seropositivity, the results may indicate that this persistence is related to past rubella outbreaks.

Entities:  

Keywords:  IgG antibody titer; congenital rubella syndrome; rubella; vaccination

Mesh:

Substances:

Year:  2021        PMID: 33642429     DOI: 10.7883/yoken.JJID.2020.542

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  1 in total

1.  Seroprevalence of anti-mumps virus IgG antibody titer and voluntary mumps vaccination coverage in young adults in Japan.

Authors:  Hiraku Sasaki; Tomoko Fukunaga; Ai Asano; Kansuke Yamanaka; Kota Oikawa; Nobuto Shibata
Journal:  Hum Vaccin Immunother       Date:  2021-04-20       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.